Texto completo
|
Autor(es): Mostrar menos - |
Valvassori, Samira S.
[1, 2]
;
Elias, Guilherme
[1, 2]
;
de Souza, Bruna
[1, 2]
;
Petronilho, Fabricia
[2, 1]
;
Dal-Pizzol, Felipe
[2, 1]
;
Kapczinski, Flavio
[1, 3, 4]
;
Trzesniak, Clarissa
[5, 1]
;
Tumas, Vitor
[5, 1]
;
Dursun, Serdar
[1, 6]
;
Nisihara Chagas, Marcos Hortes
[5, 1]
;
Hallak, Jaime E. C.
[5, 1]
;
Zuardi, Antonio W.
[5, 1]
;
Quevedo, Joao
[2, 1]
;
Crippa, Jose A. S.
[5, 1]
Número total de Autores: 14
|
Afiliação do(s) autor(es): | [1] CNPq, INCT Translat Med, Campinas, SP - Brazil
[2] Univ Extremo Sul Catarinense, Lab Neurociencias, Programa Posgrad Ciencias Saude, Unidade Acad Ciencias Saude, Criciuma, SC - Brazil
[3] Hosp Clin Porto Alegre, Bipolar Disorders Programme, Porto Alegre, RS - Brazil
[4] Hosp Clin Porto Alegre, Lab Mol Psychiat, Ctr Pesquisas, Porto Alegre, RS - Brazil
[5] Univ Sao Paulo, Dept Behav Neurosci, Div Psychiat, Ribeirao Preto Med Sch, BR-14049 Ribeirao Preto, SP - Brazil
[6] Univ Alberta, Dept Psychiat, Edmonton, AB - Canada
Número total de Afiliações: 6
|
Tipo de documento: |
Artigo Científico
|
Fonte: |
JOURNAL OF PSYCHOPHARMACOLOGY;
v. 25,
n. 2,
p. 274-279,
FEB 2011.
|
Citações Web of Science: |
25
|
Resumo |
Cannabidiol (CBD), a Cannabis sativa constituent, may present a pharmacological profile similar to mood stabilizing drugs, in addition to anti-oxidative and neuroprotective properties. The present study aims to directly investigate the effects of CBD in an animal model of mania induced by D-amphetamine (D-AMPH). In the first model (reversal treatment), rats received saline or D-AMPH (2 mg/kg) once daily intraperitoneal (i.p.) for 14 days, and from the 8th to the 14th day, they were treated with saline or CBD (15, 30 or 60 mg/kg) i.p. twice a day. In the second model (prevention treatment), rats were pretreated with saline or CBD (15, 30, or 60 mg/kg) regime i.p. twice a day, and from the 8th to the 14th day, they also received saline or D-AMPH i.p. once daily. In the hippocampus CBD (15 mg/kg) reversed the D-AMPH-induced damage and increased (30 mg/kg) brain-derived neurotrophic factor (BDNF) expression. In the second experiment, CBD (30 or 60 mg/kg) prevented the D-AMPH-induced formation of carbonyl group in the prefrontal cortex. In the hippocampus and striatum the D-AMPH-induced damage was prevented by CBD (15, 30 or 60 mg/kg). At both treatments CBD did not present any effect against D-AMPH-induced hyperactivity. In conclusion, we could not observe effects on locomotion, but CBD protect against D-AMPH-induced oxidative protein damage and increased BDNF levels in the reversal model and these effects vary depending on the brain regions evaluated and doses of CBD administered. (AU) |
|
Processo FAPESP: |
02/13197-2 - Participação do glutamato e óxido nítrico na fisiopatogenia de distúrbios neuropsiquiátricos
|
Beneficiário: | Francisco Silveira Guimaraes |
Linha de fomento: |
Auxílio à Pesquisa - Temático
|
|